Clinical Trial Update: A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for NTS071 in TP53 Y220C-mutant advanced solid tumors, assessing safety, tolerability, and preliminary efficacy in a Phase 1/2 study. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• NTS071

Snippet

Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING